Results 41 to 50 of about 31,135 (223)

Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance [PDF]

ecancermedicalscience, 2010
Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly ...
Seetharam, RN, Sood, A, Goel, S
openaire   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11 [PDF]

Anticancer Research, 2018
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC. However, patients with
Beibei, Wang, Hisanobu, Ogata, Yuto, Takishima, Shohei, Miyamoto, Hiroyuki, Inoue, Masaki, Kuroda, Kazunari, Yamada, Yasuki, Hijikata, Mutsunori, Murahashi, Hiroyuki, Shimizu, Toshihiko, Okazaki, Yoichi, Nakanishi, Kenzaburo, Tani   +12 more
openaire   +2 more sources

A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer

Experimental Cell Research, 2020
There is growing evidence to support a role for the ceramide-metabolizing enzyme, glucosylceramide synthase (GCS), in resistance to a variety of chemotherapeutic agents. Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined.
James P, Madigan, Robert W, Robey, Joanna E, Poprawski, Huakang, Huang, Christopher J, Clarke, Michael M, Gottesman, Myles C, Cabot, Daniel W, Rosenberg   +7 more
openaire   +3 more sources

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer

Cell Death and Disease, 2022
Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients.
Xiaolong Tang, Yahang Liang, Guorui Sun, Qingsi He, Zhenyu Hou, Xingzhi Jiang, Peng Gao, Hui Qu   +7 more
doaj   +1 more source

Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy

Clinical and Translational Medicine, 2022
AbstractBackgroundGastric carcinoma (GC) is one of the most deadly diseases due to tumour metastasis and resistance to therapy. Understanding the molecular mechanism of tumour progression and drug resistance will improve therapeutic efficacy and develop novel intervention strategies.MethodsDifferentially expressed long non‐coding RNAs (lncRNAs) in ...
Yu‐Feng Xiao, Bo‐Sheng Li, Jing‐Jing Liu, Su‐Min Wang, Jiao Liu, Huan Yang, Yi‐Yang Hu, Chun‐Li Gong, Ji‐Liang Li, Shi‐Ming Yang   +9 more
openaire   +3 more sources

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells

Oncotarget, 2017
Erythropoietin-producing hepatocellular receptor A2 (EphA2) is upregulated in gastric cancer tissues and cells, which is accompanied by epithelial-mesenchymal transition (EMT). The current study was designed to establish the oxaliplatin-resistant human gastric cancer cell line SGC-7901/L-OHP, to determine if EMT in these cells could be reversed, and to
Wen, Qiaocheng, Chen, Zihua, Chen, Zhikang, Chen, Jinxiang, Wang, Ran, Huang, Changhao, Yuan, Weijie   +6 more
openaire   +2 more sources

HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1

International Journal of Oncology, 2023
DNA double‑strand break repair is critically involved in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). Hepatocyte nuclear factor 1 homeobox A (HNF1A) has received increased attention regarding its role in cancer progression. The present study explored the role of HNF1A in oxaliplatin resistance in PDAC.
Xia, Renpeng, Hu, Chonghui, Ye, Yuancheng, Zhang, Xiang, Li, Tingting, He, Rihua, Zheng, Shangyou, Wen, Xiaofeng, Chen, Rufu   +8 more
openaire   +2 more sources

KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response

Cell Death and Disease, 2022
Oxaliplatin resistance is a major challenge in the treatment of colorectal cancer (CRC). Many molecular targeted drugs for refractory CRC have been developed to solve CRC drug resistance, but their effectiveness and roles in the progression of CRC and ...
Xiaohui Shen, Yuchen Zhang, Zhuoqing Xu, Han Gao, Wenqing Feng, Wenchang Li, Yiming Miao, Zifeng Xu, Yaping Zong, Jingkun Zhao, Aiguo Lu   +10 more
doaj   +1 more source

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell

Canadian Journal of Gastroenterology and Hepatology, 2021
Background. Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients.
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He   +3 more
doaj   +1 more source